Fate TherapeuticsNASDAQ: FATE

Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024.

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.

Fate Therapeutics (FATE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.54 per share a year ago.

Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen

PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently an amended securities fraud complaint was filed against Fate on behalf of certain investors who purchased shares of the company's stock between August 5, 2020 and January 5, 2023.

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.